Protocol Ledger

NCT04775953 · Phase II · COMPLETED

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Interventional Phase II clinical trial protocol NCT04775953 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-22 Enrollment: 200 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04775953
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04775953
Protocol FieldVerified Registry Value
NCT IdentifierNCT04775953
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment200 participants (ACTUAL)
Registered Start Date2021-04-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI